Beijing Konruns Pharmaceutical Co Ltd

Beijing Konruns Pharmaceutical Co., Ltd. (“Konruns Pharmaceutical”)

Established in 2003

Beijing Konruns Pharmaceutical Co., Ltd. adheres to its core mission of “Our Life Science Cares Your Health”. Over sixteen years, Konruns Pharmaceutical has developed into a high-tech pharmaceutical company that integrates R&D, production, and marketing by pursuing new drug research and development, and focusing on new special drugs. Konruns Pharmaceutical was listed on the Shanghai Stock Exchange (Stock Code: 603590) in August 2018.

Since its founding, Konruns Pharmaceutical has maintained its original work, focused on the development of new special drugs, and pursued excellence in new drug development. Currently, the Company launched Suling, a national first-in-class new drug that has been launched onto the market, and now focused developing other first-in-class new drugs, including CX1026, CX1003, and KC1036. Konruns Pharmaceutical has obtained more than 45 Chinese and international patents of invention and has been awarded several top Chinese awards, including the National 863 Program Award, China Torch Program Award, and Chinese Patent Excellence Award.